NCT06873841 Cognitive-psychophysiological Treatment for Tics in Young People With Tourette's Syndrome With or Without Biofeedback
| NCT ID | NCT06873841 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Université du Québec a Montréal |
| Condition | Tourette Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-04-15 |
| Primary Completion | 2029-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2025-04-15 with a primary completion date of 2029-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare the effectiveness of CoPs therapy with or without the therapeutic component of biofeedback in treating tics in Tourette Syndrome with emerging young adults. Hypotheses: 1. The CoPs+Biofeedback treatment will improve the severity of tics (YGTSS) and the Clinical Global Impression, surpassing the clinical significance threshold of CoPs treatment alone. 2. We expect that the identified variables (psychosocial, neurocognitive, biological) will predict the improvement of tics. Researchers will compare if the biofeedback treatment will improve the severity of tics. * In the pre-test, participants will undergo two interviews, each lasting 3 hours. These interviews will assess (through a battery of tests) the severity of tics as well as the psychosocial, biological, and neurocognitive aspects of functioning. A general assessment of intelligence and executive functions will also be conducted. * They will next attend 10 to 12 therapy sessions, with or without biofeedback. (The biofeedback component is explained in more detail in the ''Study Design'' section). * The post-test follow-ups consist of two evaluations: one 3 months after the end of the treatment and the other 6 months after. The evaluation will be done using the same battery of tests as during the pre-test interview.
Eligibility Criteria
Inclusion Criteria: * Have a diagnosis of TS or to experience bothersome tics; * Be aged 14 to 21 years inclusive at the start of therapy. Exclusion Criteria: * Present a sensorimotor impairment; * Have a diagnosis of intellectual disability (intelligence quotient below 75); * Alcohol or drug abuse; * A neurological issue (e.g., hemifacial spasms, Huntington's disease); * Change medication one month or less before step 1 and up to step 4 (last measurement time) without informing a member of the research team; * Simultaneously receive another intervention for tics (e.g., psychologist, massage therapist) without informing a research team member.
Contact & Investigator
Julie Leclerc, Psychology
PRINCIPAL INVESTIGATOR
Université du Québec à Montréal- UQAM
Frequently Asked Questions
Who can join the NCT06873841 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 21 Years, studying Tourette Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06873841 currently recruiting?
Yes, NCT06873841 is actively recruiting participants. Contact the research team at leclerc.julie@uqam.ca for enrollment information.
Where is the NCT06873841 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT06873841 clinical trial?
NCT06873841 is sponsored by Université du Québec a Montréal. The principal investigator is Julie Leclerc, Psychology at Université du Québec à Montréal- UQAM. The trial plans to enroll 150 participants.